{"id":"ingenol-mebutate-picato","safety":{"commonSideEffects":[{"rate":"80-90","effect":"Application site erythema"},{"rate":"50-70","effect":"Application site pain"},{"rate":"40-60","effect":"Application site edema"},{"rate":"30-50","effect":"Application site pruritus"},{"rate":"20-40","effect":"Application site erosion"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ingenol mebutate activates protein kinase C, leading to direct cytotoxic effects on actinic keratosis cells through mitochondrial dysfunction and rapid cell death. Additionally, it triggers an inflammatory response that recruits immune cells to the treatment area, resulting in clearance of residual diseased cells and promotion of normal skin regeneration.","oneSentence":"Ingenol mebutate is a protein kinase C (PKC) activator that induces rapid necrosis of actinic keratosis cells and promotes immune-mediated clearance of treated lesions.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:16.378Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Actinic keratosis (field treatment on face or scalp)"}]},"trialDetails":[{"nctId":"NCT02723721","phase":"PHASE2","title":"Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2016-06-15","conditions":"Lentigo Maligna","enrollment":20},{"nctId":"NCT01541553","phase":"PHASE3","title":"A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-03","conditions":"Actinic Keratosis","enrollment":367},{"nctId":"NCT01926496","phase":"PHASE4","title":"Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-09-11","conditions":"Actinic Keratosis (AK)","enrollment":485},{"nctId":"NCT01803477","phase":"PHASE1, PHASE2","title":"Safety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratosis on the Forearm","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-02","conditions":"Actinic Keratosis","enrollment":37},{"nctId":"NCT01787383","phase":"PHASE3","title":"A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-02","conditions":"Actinic Keratosis","enrollment":200},{"nctId":"NCT02377999","phase":"PHASE2","title":"Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-02","conditions":"Anogenital Warts","enrollment":40},{"nctId":"NCT02406014","phase":"PHASE4","title":"Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-04","conditions":"Actinic Keratosis (AK)","enrollment":502},{"nctId":"NCT03546166","phase":"PHASE2","title":"Study Evaluating the Efficacy and Safety of 0.05% Ingenol Mebutate (Picato® 500) in the Treatment of Basal Cell Carcinoma","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2018-07-26","conditions":"Carcinoma","enrollment":24},{"nctId":"NCT04202445","phase":"","title":"TreatMent of ActInic KerAtosis Lesions : pharmacoepiDemiological Study of the Impact in Real Life of ingenOl Mebutate Gel (Picato®) on Patients Satisfaction","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2014-04","conditions":"Actinic Keratosis","enrollment":1218},{"nctId":"NCT02654769","phase":"PHASE3","title":"A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2015-02","conditions":"Actinic Keratosis","enrollment":441},{"nctId":"NCT03200912","phase":"PHASE3","title":"An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2016-08-19","conditions":"ACTINIC KERATOSIS","enrollment":507},{"nctId":"NCT02090465","phase":"","title":"Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-07","conditions":"Actinic Keratosis","enrollment":840},{"nctId":"NCT02421471","phase":"","title":"PMS to Evaluate the Safety and Efficacy of Picato® Gel","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2014-09","conditions":"Actinic Keratosis","enrollment":1324},{"nctId":"NCT02354391","phase":"PHASE2","title":"Ingenol Mebutate (Picato®) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Keratosis","status":"UNKNOWN","sponsor":"Pacific Dermaesthetics","startDate":"2015-01","conditions":"Actinic Keratosis","enrollment":20},{"nctId":"NCT02594436","phase":"","title":"The Use of Picato® (Ingenol Mebutate) to Treat Actinic Keratosis in Standard Clinical Practice","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-12-01","conditions":"Actinic Keratosis","enrollment":440},{"nctId":"NCT03508856","phase":"NA","title":"Clinical and Histologic Evaluation of Picato 0.15% Gel in the Cosmetic Improvement of Photoaged Skin","status":"COMPLETED","sponsor":"Skin Laser & Surgery Specialists","startDate":"2015-11-09","conditions":"Actinic Keratosis, Photo-aged Skin","enrollment":23},{"nctId":"NCT02716714","phase":"PHASE4","title":"Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis","status":"COMPLETED","sponsor":"Korea University","startDate":"2015-04","conditions":"Actinic Keratosis","enrollment":77},{"nctId":"NCT02748902","phase":"PHASE1","title":"Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.","status":"COMPLETED","sponsor":"Neal D. Bhatia, MD","startDate":"2016-04-27","conditions":"Verruca Vulgaris, Common Warts","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Picato","RLD"],"phase":"phase_3","status":"active","brandName":"Ingenol Mebutate (Picato®)","genericName":"Ingenol Mebutate (Picato®)","companyName":"Actavis Inc.","companyId":"actavis-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ingenol mebutate is a protein kinase C (PKC) activator that induces rapid necrosis of actinic keratosis cells and promotes immune-mediated clearance of treated lesions. Used for Actinic keratosis (field treatment on face or scalp).","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}